Loading briefing details...
News Brief
By: PointLine Media Research & Editorial Team
Category:Business,Health,Science & Environment
November 17, 2026
This study is a breakthrough in oncology, shifting the focus toward metabolic-immune crosstalk. By identifying MOCCI as a driver of metastasis, researchers have uncovered a druggable target that could prevent cancer spread. This insight paves the way for precision therapies that halt disease progression at the source.
Researchers from Fudan University Shanghai Cancer Center have identified a critical mechanism driving lung cancer progression. The study, published in Cancer Biology & Medicine, highlights a specific subgroup of metastatic cancer cells characterized by MOCCI-driven oxidative phosphorylation. By modulating mitochondrial respiration, MOCCI fuels the spread of lung cancer cells to lymph nodes, significantly impacting patient prognosis and survival rates.
The research team utilized advanced single-cell RNA sequencing and spatial transcriptomics to uncover how these metabolically rewired cells interact with the immune system. Specifically, MOCCI-positive cells increase secretion of the protein GDF15. This signaling molecule interacts with TGFBR2 on follicular helper T cells, triggering immune exhaustion and suppressing the activation of essential B cells, thereby creating a tumor-promoting microenvironment.
These findings provide a vital roadmap for future therapeutic interventions. By targeting the MOCCI-driven metabolic pathway, clinicians may be able to disrupt the communication between malignant cells and the immune system, effectively intercepting metastasis. This discovery underscores the importance of metabolic adaptation in cancer dissemination and offers a promising new target for improving clinical outcomes in lung adenocarcinoma patients.